Deutsch English Français

Contact

EP3139932

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP3139932

EP3139932 - TREATMENT REGIMEN FOR TIACUMICIN COMPOUND [Right-click to bookmark this link]
Former [2017/11]	TREATMENT REGIMEN TIACUMICIN COMPOUND
	[2018/01]
Status	No opposition filed within time limit Status updated on 07.06.2019 Database last updated on 31.03.2026
Former	The patent has been granted Status updated on 29.06.2018
Former	Grant of patent is intended Status updated on 14.03.2018
Former	Request for examination was made Status updated on 10.02.2017
Former	The international publication has been made Status updated on 13.12.2016
Most recent event Tooltip	07.06.2019	No opposition filed within time limit	published on 10.07.2019 [2019/28]
Applicant(s)	For all designated states Astellas Pharma Europe Ltd. 2000 Hillswood Drive Chertsey, Surrey KT16 0RS / GB
	[2017/11]
Inventor(s)	01 / KARAS, Andreas Johannis c/o Astellas BV Sylviusweg 62 NL-2333 BE Leiden / NL
	02 / LONGSHAW, Christopher Mark c/o Astellas BV Sylviusweg 62 NL-2333 BE Leiden / NL
	[2017/11]
Representative(s)	Schmid, Ulrike Astellas B.V. Sylviusweg 62 2333 BE Leiden / NL
	[2017/11]
Application number, filing date	15731245.5	11.05.2015
	[2017/11]
	WO2015EP00965
Priority number, date	EP20140075031	09.05.2014 Original published format: EP 14075031
	[2017/11]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2015169451
	Date:	12.11.2015
	Language:	EN
	[2015/45]
	Type:	A1 Application with search report
	No.:	EP3139932
	Date:	15.03.2017
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 12.11.2015 takes the place of the publication of the European patent application.
	[2017/11]
	Type:	B1 Patent specification
	No.:	EP3139932
	Date:	01.08.2018
	Language:	EN
	[2018/31]
Search report(s)	International search report - published on:	EP	12.11.2015
Classification	IPC:	A61K31/7048, A61P31/04	[2017/11]
	CPC:	A61K31/7048 (EP,IL,KR,US); A61K9/0053 (IL,KR); A61K9/28 (IL,US); A61P1/00 (EP,IL); A61P1/12 (EP,IL); A61P31/00 (EP,IL); (+) A61P31/04 (EP,IL) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/11]
Extension states	BA	06.12.2016
	ME	06.12.2016
Validation states	MA	06.12.2016
Title	German:	BEHANDLUNGSSCHEMA MIT TIACUMICINVERBINDUNGEN	[2017/11]
	English:	TREATMENT REGIMEN FOR TIACUMICIN COMPOUND	[2018/01]
	French:	PROGRAMME DE TRAITEMENT POUR COMPOSÉ DE TIACUMICIN	[2018/01]
	Former [2017/11]	TREATMENT REGIMEN TIACUMICIN COMPOUND
	Former [2017/11]	COMPOSÉ DE TIACUMICINE ET RÉGIME DE TRAITEMENT ASSOCIÉ
Entry into regional phase	06.12.2016	National basic fee paid
	06.12.2016	Designation fee(s) paid
	06.12.2016	Examination fee paid
Examination procedure	06.12.2016	Examination requested [2017/11]
	06.12.2016	Date on which the examining division has become responsible
	29.06.2017	Amendment by applicant (claims and/or description)
	15.03.2018	Communication of intention to grant the patent
	25.06.2018	Fee for grant paid
	25.06.2018	Fee for publishing/printing paid
	25.06.2018	Receipt of the translation of the claim(s)
Opposition(s)	03.05.2019	No opposition filed within time limit [2019/28]
Fees paid	Renewal fee
	30.05.2017	Renewal fee patent year 03
	29.05.2018	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	SM	01.08.2018
	[2019/26]
Cited in	International search	[YD] SORIANO ET AL.: "Abstract: The use of a fidaxomicin chaser as effective salvage therapy for vancomycin-refractory, recurrent Clostridium difficile infections (IDWeek 2013)", 5 October 2013 (2013-10-05), XP055182724, Retrieved from the Internet [retrieved on 20150414] [YD] 1-21 * the whole document *
		[YD] MELINDA M SORIANO ET AL: "The Use of a Fidaxomicin Taper/Pulsed Chaser as Effective Salvage Therapy for Vancomycin-Refractory, Recurrent Clostridium difficile Infections", 5 October 2013 (2013-10-05), XP055182720, Retrieved from the Internet [retrieved on 20150414]
		[YD] C. CHILTON ET AL: "2013: K-336. Comparison of Extended Duration Fidaxomicin Dosing Regimens for Treatment of Clostridium difficile Infection (CDI) in an in vitro Gut Model", September 2013 (2013-09-01), XP055182841, Retrieved from the Internet [retrieved on 20150414] [YD] 1-21 * the whole document *
		[YD] C. H. CHILTON ET AL: "Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 69, no. 2, 3 September 2013 (2013-09-03), pages 451 - 462, XP055182651, ISSN: 0305-7453, DOI: 10.1093/jac/dkt347 [YD] 1-21 * abstract * DOI: http://dx.doi.org/10.1093/jac/dkt347
		[A] S. JOHNSON ET AL: "Fidaxomicin "Chaser" Regimen Following Vancomycin for Patients With Multiple Clostridium difficile Recurrences", CLINICAL INFECTIOUS DISEASES, vol. 56, no. 2, 28 September 2012 (2012-09-28), pages 309 - 310, XP055182579, ISSN: 1058-4838, DOI: 10.1093/cid/cis833 [A] 1-21 * page 2, column r * DOI: http://dx.doi.org/10.1093/cid/cis833
		[A] THER ADV: "Therapeutic Advances in Gastroenterology Review", 2012, pages 395 - 402, XP055182638, Retrieved from the Internet [A] 1-21 * page 400 *
		[Y] G. W. TANNOCK ET AL: "A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin", MICROBIOLOGY, vol. 156, no. 11, 19 August 2010 (2010-08-19), pages 3354 - 3359, XP055182699, ISSN: 1350-0872, DOI: 10.1099/mic.0.042010-0 [Y] 1-21 * page 3358 * DOI: http://dx.doi.org/10.1099/mic.0.042010-0
		[Y] T. J. LOUIE ET AL: "Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI", CLINICAL INFECTIOUS DISEASES, vol. 55, no. suppl 2, 2 July 2012 (2012-07-02), pages S132 - S142, XP055205254, ISSN: 1058-4838, DOI: 10.1093/cid/cis338 [Y] 1-21 * page s137 * DOI: http://dx.doi.org/10.1093/cid/cis338
		[XP] "Efficacy of tapered fidaxomicin dosing regimens to treat simulated Clostridium difficile infection (CDI) in an in vitro gut model", 14 May 2014 (2014-05-14), XP055182784, Retrieved from the Internet [retrieved on 20150414] [XP] 1-21 * the whole document *
		[YP] M. M. SORIANO ET AL: "Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies", OPEN FORUM INFECTIOUS DISEASES, vol. 1, no. 2, 1 August 2014 (2014-08-01), pages ofu069 - ofu069, XP055182559, DOI: 10.1093/ofid/ofu069 [YP] 1-21 * pages 5-6 * DOI: http://dx.doi.org/10.1093/ofid/ofu069
		[T] C. H. CHILTON ET AL: "Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 14 June 2015 (2015-06-14), XP055205152, ISSN: 0305-7453, DOI: 10.1093/jac/dkv156 [T] * page 9 * DOI: http://dx.doi.org/10.1093/jac/dkv156
	by applicant	S. NIU ET AL., CHEMBIOCHEM, vol. 12, 2011, pages 1740 - 1748 [Y] 1-21 * page s137 *
		WIEGAND P.N.; NATHWANI D.; WILCOX M.H. ET AL., J. HOSP INFECT, 10 April 2012 (2012-04-10)
		GHANTOJI S.S.; SAIL, K.; LAIRSON D.R., J. HOSP. INFECT., vol. 74, 2010, pages 309 - 318 [XP] 1-21 * the whole document *
		MCFARLAND LV: "Epidemiology, risk factors and treatments for antibiotic-associated diarrhea", DIG DIS, vol. 16, 1998, pages 292 - 307 [YP] 1-21 * pages 5-6 *
		WISTROM J; NORRBY SR; MYHRE E ET AL.: "Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study", J ANTIMICROB CHEMOTHER, vol. 47, 2001, pages 43 - 50 [T] * page 9 *
		CROOK ET AL., CLIN. INFECT. DIS., vol. 55, no. 2, 2012, pages 93 - 103
		T. LOUIE ET AL., 22ND EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 31 March 2012 (2012-03-31)
		T.J. LOUIE ET AL., CLIN. INFECT. DIS., vol. 55, no. S2, 2012, pages 132 - 142
		TANNOCK, MICROBIOLOGY, vol. 156, 2010, pages 3354 - 3359
		SORIANO ET AL., EXP REV ANTIINFTHER, vol. 1, 2013, pages 767 - 776
		M.M. SORIANO ET AL., ABSTRACT 42591; PRESENTATION NO. 1410; IDWEEK, 5 October 2013 (2013-10-05)
		C.H. CHILTON ET AL., J. ANTIMICROBIAL CHEMOTHERAPY ADVANCE ACCESS, September 2013 (2013-09-01)
		C.H. CHILTON ET AL., 23RD EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASE, 27 April 2013 (2013-04-27)
		MACFARLANE ET AL., MICROBIAL ECOLOGY, vol. 35, 1998, pages 180 - 187
		IUPAC RECOMMENDATIONS 1996, PURE & APPLIED CHEMISTRY, vol. 68, 1996, pages 2193 - 2222
		L. LACHMAN ET AL.: "The Theory and Practice of Industrial Pharmacy", 1986
		"Remington's Pharmaceutical Science", 1990, pages: 1644
		"Remington's Pharmaceutical Sciences", 1990, pages: 1666
		FREEMAN J; O'NEILL FJ; WILCOX MH: "The effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut", J ANTIMICROB CHEMOTHER, vol. 52, 2003, pages 96 - 102
		BAINES SD; FREEMAN J; WILCOX MH: "Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model", J ANTIMICROB CHEMOTHER, vol. 55, 2005, pages 974 - 82

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.